Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human NDMM MHC-I immunopeptidome mass spectrometry

ABSTRACT: To assess the contribution of ribosome profiling-detected nuORFs in NDMM to the MHC-I immunopeptidome and their potential for generating neoantigens, we obtained MHC-I immunopeptidome mass spectrometry (MS/MS) spectra from three patients with NDMM.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Dong Wang

LAB HEAD: Dong Wang

PROVIDER: PXD047053 | Pride | 2025-02-20

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	NDMM_HLAI_P1.zip	Other
	NDMM_HLAI_P2.zip	Other
	NDMM_HLAI_P3.zip	Other
	Search.result.zip	Other

Items per page:

1 - 4 of 4

Similar Datasets

A complete peptidome workflow for neoantigen identification and validation by mass spectrometry-based immunopeptidomics

Project description:We proposed a complete workflow for neoantigen identification and validation based solely on MS immunopeptidomics.We first developed a new Neo DiscoveryTM immunopeptidome enrichment Kit, which can be used for HLA peptide purification from a small amount of biopsied tissue as low as 18mg. To achieve high sensitivity with such a low amount of sample, we leveraged the power of deep learning and a massive amount of MS-based immunopeptidomics data to build DeepNovo-HLA, a de novo sequencing model specialized for HLA peptides. We also developed DeepImmu, a personalized model for immunogenicity prediction based on the central tolerance of T cells, i.e. the positive and negative selection of T cells in an individual patient.

2024-05-04 | PXD046370 | Pride

Multiple classes of antigen contribute to the antigenic landscape of mesothelioma

Project description:Mesothelioma is an incurable, asbestos-exposure related cancer that typically affects the lining or pleura of the lungs. Symptoms typically develop many decades after initial exposure to asbestos, leaving an enduring legacy of disease. Vaccine-induced augmentation of immune responses unleashed during checkpoint blockade may provide further clinical benefit in mesothelioma. In this study we explore the HLA class I antigenic landscape (or immunopeptidome) of mesothelioma in patient derived cell line and clinical material (pleural effusion samples).

2025-05-07 | PXD054498 | Pride

T1D B lymphocyte cell line Immunopeptidome

Project description:HLA-I and HLA-II immunopeptidome of B cells from healthy control and Type 1 diabetics sharing similar HLA alleles.

2022-02-14 | PXD026184 | Pride

Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

Project description:HLA-presented antigenic peptides are central components of T cell-based immunity in infectious disease. Beside HLA molecules on cell surfaces, soluble HLA molecules (sHLA) are released in the blood suggested to impact cellular immune responses. We demonstrated that sHLA levels were significantly increased in COVID-19 patients and convalescent individuals compared to a control cohort and positively correlated with SARS CoV-2-directed cellular immunity. Of note, patients with severe courses of COVID-19 showed reduced sHLA levels. Mass spectrometry-based characterization of sHLA-bound antigenic peptides, the so called soluble immunopeptidome, revealed a COVID-19-associated increased diversity of HLA-presented peptides and identified a naturally presented SARS-CoV-2-derived peptide from the viral nucleoprotein in the plasma of COVID-19 patients. Interestingly, sHLA serum levels directly correlated with the diversity of the soluble immunopeptidome. Together, these findings suggest an inflammation-driven release of sHLA in COVID-19, directly influencing the diversity of the soluble immunopeptidome with implications for SARS-CoV-2-directed T cell-based immunity and disease outcome.

2022-11-23 | PXD029567 | Pride

Kinetics of abacavir-induced remodelling of the Major Histocompatibility Complex class I peptide repertoire

Project description:Characterisation of the kinetics of abacavir-induced perturbation of the immunopeptidome of the Major Histocompatibility Complex (MHC) class I molecule HLA-B*57:01.

2021-05-11 | PXD024331 | Pride

Naturally presented benzypenicillin-modified HLA-A*02:01 ligands

Project description:This study characterised the array of benzylpenicillin-modified ligands within the immunopeptidome of HLA-A*02:01. We further describe a novel target of penicillin within the immunopeptidome and proteome. Identification of penicillin-modified ligands within the immunopeptidome will allow future immunogenicity assays to aid in understanding how T cells can mediate penicillin-induced hypersensitivities.

2025-10-01 | PXD065200 | Pride

Rational engineering of minimally immunogenic nucleases for gene therapy

Project description:Genome editing using CRISPR-Cas systems is a promising avenue for the treatment of genetic diseases. However, cellular and humoral immunogenicity of genome editing tools, which originate from bacteria, complicates their clinical use. Here we report reduced immunogenicity (Red)(i)-variants of two clinically-relevant nucleases, SaCas9 and AsCas12a. Through MHC-associated peptide proteomics (MAPPs) analysis, we identified putative immunogenic epitopes on each nuclease. Then, we used computational modeling to rationally design these proteins to evade the immune response. SaCas9 and AsCas12a Redi variants were substantially less recognized by adaptive immune components, including reduced binding affinity to MHC molecules and attenuated generation of cytotoxic T cell responses, while maintaining wild-type levels of activity and specificity. In vivo editing of PCSK9 with SaCas9.Redi.1 was comparable in efficiency to wild-type SaCas9, but significantly reduced undesired immune responses. This demonstrates the utility of this approach in engineering proteins to evade immune detection.

2024-11-07 | PXD054579 | Pride

Immunopeptidome of HeLa-CIITA cells silenced for TAX1BP1(T6BP) expression

Project description:CD4+ T lymphocytes play a major role in the establishment and maintenance of immunity. They are activated by antigenic peptides derived from extracellular or newly synthesized (endogenous) proteins presented on the surface of antigen presenting cells (APCs) by the MHC-II molecules. The pathways leading to endogenous MHC-II presentation remain poorly characterized. We demonstrate here that the autophagy receptor, T6BP, influences both autophagy-dependent and -independent endogenous presentation of HIV- and HCMV-derived peptides. By studying the immunopeptidome of MHC-II molecules, we show that T6BP affects both the quantity and quality of peptides presented. T6BP silencing induces mislocalization of the MHC-II-loading compartments and a rapid degradation of the invariant chain (CD74) without altering the expression and internalization kinetics of MHC-II molecules. T6BP also controls the ER localization of the chaperone calnexin that we identified as a T6BP partner. Remarkably, calnexin silencing in APCs replicates the functional consequences of T6BP silencing: decreased CD4+ T cell activation and exacerbated CD74 degradation. Altogether, we unravel T6BP as a key player of the MHC-II-restricted endogenous presentation pathway and we propose one potential mechanism of action.

2022-09-22 | PXD024417 | Pride

Immunopeptidome of an acute myeloid leukemia cell line THP1

Project description:We report the use of complementary peptide antigen enrichment and comprehensive mass spectrometric acquisition strategies to provide in-depth immunopeptidome data for AML cell line THP1

2020-05-13 | PXD015039 | Pride

Deep Exploration of the Immunopeptidome of a Pancreatic Cancer Cell Line Panc1: Implications for Clinical Immunopeptidomics and Immunotherapy (DDA datasets)

Project description:Pancreatic ductal adenocarcinoma (PDAC), with its devastating prognosis and limited treatment options, necessitates innovative therapeutic strategies. T-cell-based immunotherapy has shown promise for various cancers, including PDAC. Thus, a comprehensive understanding of the HLA-peptidome in PDAC is essential to pave the way for the effective design of immunotherapy and other interventions. In this study, we employed off-line high-pH reverse-phase (HPH-RP) fractionation of peptides extracted from immunoaffinity purified HLA class I molecules isolated from the surface of Panc1 cells in the absence and presence of cytokine stimulation. We demonstrate that this strategy is a relatively simple and rapid technique that significantly expands the depth of coverage of the PDAC immunopeptidome using data-dependent acquisition strategies and allowing the identification of more potentially actionable peptide antigens. Whilst cell lines provide an abundant source of material for immunopeptidomics analysis, clinical samples and biopsies from pancreatic cancer patients typically involve much smaller amounts of material. Thus, we performed a proof of concept study and demonstrated that immunopeptidome characterization was feasible from cell pellets of only 1 million cells (equivalent to approximately 1mg of tissue), using a spectral library generated from the HPH-RP fractionated material and the ZenoSWATH DIA-MS workflow on the SCIEX 7600 ZenoToF system. These studies form the basis for future clinical translational immunopeptidomics approaches to screen tumor antigen presentation in PDAC biopsies and provide new opportunities for immune-based therapies.

2025-07-14 | PXD054360 | Pride